'김갑성' 기자의 전체기사
-
KPM Analytics Unveils the SmartChem® 800 Series, a Next-Gene…
Industry's highest-capacity discrete analyzer delivers true walk-away automation for commercial laboratories WESTBOROUGH, Mass., Dec. 16, 2025 -- Commercial laboratories face mounting pressure to process more samples with fewer staff while maintaining fast turnaround times. When urgent samples arrive midday, labs face an impossible choice: disrupt current analyses to accommodate rush orders, or make clients wait. Meanwhile, technicians spend hours monitoring instruments and managing complex workflows across multiple analyzers—an unsustainable approach given persistent staffing
- 김갑성 기자
- 2025-12-16 22:00
-
Allink Biotherapeutics Completes $47M Extension Rounds of…
The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials The financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing critical limitations of existing biologic therapeutics SHANGHAI, Dec. 16, 2025 -- Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company focusing on developi
- 김갑성 기자
- 2025-12-16 21:30
-
Breakthrough Progress: METiS TechBio Publishes Consec…
BEIJING, Dec. 16, 2025 -- METiS TechBio ("METiS") today announced that two of its oncology pipeline candidates, MTS-105 and MTS-107, have been published in leading international peer-reviewed journals, Nature Communications and the Journal for ImmunoTherapy of Cancer (JITC), representing two major breakthroughs in mRNA-based cancer therapeutics. Both studies leverage METiS's proprietary AI-powered NanoForge platform, which introduces a precision-guided rocket-and-payload delivery analogy. By combining liver- and spleen-targeted lipid nanoparticle (LNP) delivery system
- 김갑성 기자
- 2025-12-16 18:59
-
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves F…
SAN FRANCISCO, Dec. 16, 2025 -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key oversea clinical studies: the U.S. pivotal clinical study (NCT06764940) of Utidelone Injection(UTD1) combined with capecitabine for the treatment of HER2-negative breast cancer brain metastases (BCBM). The study adopts a two-stage design and plans to enroll approximately 120 subjects. The primary endpoint is the central nervous system objective response rate (CN
- 김갑성 기자
- 2025-12-16 12:55
-
Allink Biotherapeutics Completes $47M Extension Rounds of…
The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials The financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing critical limitations of existing biologic therapeutics SHANGHAI, Dec. 16, 2025 -- Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company focusing on developi
- 김갑성 기자
- 2025-12-16 08:30
-
Titomic Secures Early Manufacturing Development Contract w…
HUNTSVILLE, Ala., Dec. 16, 2025 -- Titomic Limited (ASX: TTT), a global leader in cold spray additive manufacturing utilizing their Titomic Kinetic Fusion™ technology, is pleased to announce it has secured an Early Manufacturing Development (EMD) contract with a leading defense prime contractor to support a new effort for production of next-generation defense articles. The collaboration will establish and validate an innovative manufacturing approach intended to accelerate production, improve supply-chain resilience, and deliver critical components to the warfighter faster. The initia
- 김갑성 기자
- 2025-12-16 06:59
-
Enginprime Medical Inc Announces First-in-Human Study of I…
HANGZHOU, China, Dec. 16, 2025 -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that its industry leading pVAD, OpusOne™, has entered its first-in-human clinical study at The Second Affiliated Hospital, School of Medicine, Zhejiang University ("SAHZU"). This milestone marks the first clinical evaluation of the device's safety and performance in patients. PVAD supports the cardiac output via a percutaneously implanted pump, reduces the l
- 김갑성 기자
- 2025-12-16 06:00
-
Miroma Project Factory: Powers Clinical-Grade App for One of A…
SYDNEY, Dec. 16, 2025 -- Miroma Project Factory (MPF) has delivered a bespoke mobile solution for Screen2Quit, part of the International Lung Study trial and one of Australia's most ambitious research studies targeting smoking cessation in people undergoing lung cancer screening. Commissioned by the Thoracic Research Centre at the University of Queensland and developed in partnership with Queensland Health, Screen2Quit is a revised, clinical version of the My QuitBuddy application redeveloped and instrumented to collect participant backend data for a multi-year randomised contr
- 김갑성 기자
- 2025-12-16 05:07
-
HitGen Submits Commitment Letter to Science Based Targets i…
CHENGDU, China, Dec. 15, 2025 -- HitGen Inc. (hereinafter referred to as "HitGen", SSE: 688222.SH), announced it has officially submitted its commitment letter to the Science Based Targets initiative (SBTi). HitGen has pledged to set near-term science-based targets within the next two years, aligned with the SBTi's stringent criteria. This commitment entails the future development and implementation of a series of emission reduction measures designed to cut the company's greenhouse gas emissions across its value chain to a level consistent with the 1.5°C temperature goal
- 김갑성 기자
- 2025-12-15 22:30
-
PM-International expands child sponsorships to 8,000 with €…
SCHENGEN, Luxembourg, Dec. 15, 2025 -- Global support for children in need is declining rapidly. According to World Vision, governments and institutions worldwide have cut funding for children's aid by $16.3 billion, limiting access to food, healthcare and education for millions of vulnerable children. At the same time, PM-International is expanding its commitment through its charity Foundation PM We Care. In 2026, it will increase the commitment to the partnership with World Vision by supporting an additional 1,400 children, raising the total number of sponsored children to 8,0
- 김갑성 기자
- 2025-12-15 22:13
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 5하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 6대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 7만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-01-31_SAT
- Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery" 16:15
- CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK 12:05
- Origin Agritech Announces Fiscal Year 2025 Results 06:00
- White Pearl Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering 05:47
- Planet Green Holdings Corp. Provides Response to Unusual Market Action 05:05
- SKF completes previously announced divestment of non-core aerospace operation in Elgin, USA 03:36
- DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion 03:34
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 01월 31일 17시 40분